CENTRAL TRUST Co Sells 1,615 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

CENTRAL TRUST Co decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,974 shares of the medical research company's stock after selling 1,615 shares during the quarter. CENTRAL TRUST Co's holdings in Thermo Fisher Scientific were worth $11,930,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. FPC Investment Advisory Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $28,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $30,000. Finally, Noble Wealth Management PBC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $35,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. UBS Group decreased their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $405.15 on Tuesday. The firm's 50-day simple moving average is $416.55 and its two-hundred day simple moving average is $491.11. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market cap of $152.94 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.